Medpace Holdings, Inc. (NASDAQ:MEDP) Given Average Rating of “Hold” by Analysts

Medpace Holdings, Inc. (NASDAQ:MEDP) has received a consensus recommendation of “Hold” from the fifteen ratings firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, ten have issued a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price among analysts that have covered the stock in the last year is $467.0833.

MEDP has been the subject of a number of research reports. BMO Capital Markets decreased their price objective on Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a research report on Friday, April 24th. Robert W. Baird decreased their price objective on Medpace from $565.00 to $477.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Barclays decreased their price objective on Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a research report on Friday, April 24th. Wall Street Zen lowered Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Finally, Weiss Ratings lowered Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, April 6th.

Medpace Stock Performance

Shares of NASDAQ MEDP opened at $460.20 on Friday. Medpace has a one year low of $301.90 and a one year high of $628.92. The firm has a market capitalization of $13.14 billion, a PE ratio of 28.93, a PEG ratio of 2.33 and a beta of 1.18. The business has a 50-day moving average price of $452.12 and a two-hundred day moving average price of $499.49.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The firm had revenue of $706.60 million during the quarter, compared to analyst estimates of $697.82 million. During the same period last year, the company posted $3.67 EPS. The business’s quarterly revenue was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Research analysts anticipate that Medpace will post 17.04 EPS for the current year.

Insider Buying and Selling

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the sale, the general counsel directly owned 20,343 shares in the company, valued at $9,154,350. The trade was a 44.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 20.50% of the company’s stock.

Institutional Investors Weigh In On Medpace

Institutional investors have recently made changes to their positions in the company. Optiver Holding B.V. acquired a new stake in shares of Medpace during the 3rd quarter valued at about $27,000. Steigerwald Gordon & Koch Inc. acquired a new stake in shares of Medpace during the 4th quarter valued at about $30,000. Elyxium Wealth LLC acquired a new stake in shares of Medpace during the 4th quarter valued at about $30,000. Quarry LP acquired a new stake in shares of Medpace during the 3rd quarter valued at about $35,000. Finally, Bayban acquired a new stake in shares of Medpace during the 4th quarter valued at about $44,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.